August 2018 tender notification

Tender Closed

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2016/17 Invitation to Tender, dated 3 November 2016 and the 2017/18 Invitation to Tender, dated 2 November 2017.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2017/18 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2021

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to currently listed pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name Presentation;
Pack size and type
Current
pack price
New
pack price
Sole supply brand (Supplier) Date of listing Date of reference pricing of other listed brands Sole Subsidised Supply date Brand (Supplier) affected by reference pricing and delisting
Filgrastim Inj 300 mcg per 0.5 ml prefilled syringe, 10 prefilled syringe $270.00
(per 5 prefilled syringe)
$96.22 Nivestim
(Pfizer)
1 March 2019 1 May 2019 1 August 2019 Zarzio
(Novartis)
Filgrastim Inj 480 mcg per 0.5 ml prefilled syringe, 10 prefileld syringe $432.00
(per 5 prefilled syringe)
$161.50 Nivestim
(Pfizer)
1 March 2019 1 May 2019 1 August 2019 Zarzio
(Novartis)
Moclobemide Tab 150 mg, 60 tablet blsiter pack $85.10
(per 500 tab)
$6.40 Aurorix
(Mylan)
1 February 2019 1 April 2019 1 July 2019 Apo-Moclobemide
(Apotex)
Moclobemide Tab 300 mg, 60 tablet blister pack $30.70
(per 100 tab)
$9.80 Aurorix
(Mylan)
1 February 2019 1 April 2019 1 July 2019 Apo-Moclobemide
(Apotex)
Sodium fusidate [fusidic acid] Crm 2%, 5 g tube OP $2.52
(per 15 g)
$1.59 Foban
(AFT)
1 March 2019 n/a 1 August 2019 DP Fusidic Acid Cream (15 g)
(AFT)
Sodium fusidate [fusidic acid] Oint 2%, 5 g tube OP $3.45
(per 15 g)
$1.59 Foban
(AFT)
1 March 2019 n/a 1 August 2019 Foban (15 g)
(AFT)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name Presentation;
Pack size and type
Current pack price New pack price Hospital supply brand
(Supplier)
DV
Limit
Listing date Hospital Supply Status date Brand (Supplier) affected by delisting
Filgrastim Inj 300 mcg in 0.5 ml prefilled syringe, 10 prefilled syringe $270.00
(per 5 prefilled syringe)
$96.22 Nivestim
(Pfizer)
1% 1 March 2019 1 May 2019 Zarzio
(Novartis)
Filgrastim Inj 480 mcg in 0.5 ml prefilled syringe, 10 prefilled syringe $432.00
(per 5 prefilled syringe)
$161.50 Nivestim
(Pfizer)
1% 1 March 2019 1 May 2019 Zarzio
(Novartis)
Moclobemide Tab 150 mg, 60 tablet blister pack $85.10
(per 500 tab)
$6.40 Aurorix
(Mylan)
1% 1 February 2019 1 April 2019 Apo-Moclobemide
(Apotex)
Moclobemide Tab 300 mg, 60 tablet blister pack $30.70
(per 100 tab)
$9.80 Aurorix
(Mylan)
1% 1 February 2019 1 April 2019 Apo-Moclobemide
(Apotex)
Sodium fusidate [fusidic acid] Crm 2%, 5 g tube $2.52
(per 15 g)
$1.59 Foban
(AFT)
1% 1 March 2019 1 May 2019 DP Fusidic Acid Cream (15 g) (AFT)
Sodium fusidate [fusidic acid] Oint 2%, 5 g tube $3.45
(per 15 g)
$1.59 Foban
(AFT)
1% 1 March 2019 1 May 2019 Foban (15 g)
(AFT)

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:

  • the 2016/17 Invitation to Tender, dated 3 November 2016, and
  • the 2017/18 Invitation to Tender, dated 2 November 2017.

2016/17 Invitation to Tender

Chemical name Line item
Bupivacaine hydrochloride with adrenaline Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml sterile pack
Bupivacaine hydrochloride with adrenaline Inj 5 mg per ml with adrenaline 1:200,000, 20 ml sterile pack
Metoclopramide hydrochloride Inj 5 mg per ml, 2 ml ampoule
Trimethorpiem with sulphamethoxazole
[Co-trimoxazole]
Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml

2017/18 Invitation to Tender

Chemical name Line item
Ferrous sulphate with ascorbic acid Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg
Filgrastim Inj 120 mcg per ml, 0.5 ml prefileld syringe

For products included in the 2016/17 and 2017/18 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.